
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. has demonstrated a notable increase in the volume of EsoGuard tests processed, with a climb from 2,756 tests in Q2 to 2,841 in Q3, indicating a positive growth trend in its Diagnostics segment. The company's current valuation presents an attractive opportunity, especially as it anticipates significant growth in its medical devices and digital health segments moving into 2025 and 2026. With a balanced risk-reward profile highlighted by the upward trajectory of its testing figures and projections for substantial future growth, PAVmed is positioned favorably within the medical technology market.
Bears say
PAVmed Inc reported a pro forma net loss of $0.8 million in its recent quarter, signaling financial challenges as earnings per share fell to $(0.05), deviating negatively from both internal and consensus estimates. The company experienced a decline in its EsoGuard tests, processing only 2,756 tests in Q2 compared to 3,034 in Q1 and a higher volume in previous quarters, indicating potential issues in product uptake and market demand. Furthermore, PAVmed faces substantial risks impacting its growth prospects, including liquidity issues, regulatory hurdles, commercialization challenges, and increased competition within the medical technology sector.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares